Techniques in Vascular & Interventional Radiology
Volume 13, Issue 1 , Pages 2-10 , March 2010

Comprehensive Evaluation and Medical Management of Infrainguinal Peripheral Artery Disease: “When to Treat, When Not to Treat”

  • Thomas J. Kiernan, MD

      Affiliations

    • Section of Vascular Medicine, Division of Cardiology, Massachusetts General Hospital, Boston, MA
    • ,
  • Brian G. Hynes, MD

      Affiliations

    • Section of Vascular Medicine, Division of Cardiology, Massachusetts General Hospital, Boston, MA
    • ,
  • Nicholas J. Ruggiero, MD

      Affiliations

    • Section of Vascular Medicine, Division of Cardiology, Massachusetts General Hospital, Boston, MA
    • ,
  • Bryan P. Yan, MD

      Affiliations

    • Section of Vascular Medicine, Division of Cardiology, Massachusetts General Hospital, Boston, MA
    • ,
  • Michael R. Jaff, DO

      Affiliations

    • Section of Vascular Medicine, Division of Cardiology, Massachusetts General Hospital, Boston, MA
    • The Vascular Center, Massachusetts General Hospital, Boston, MA
    • Corresponding Author InformationAddress reprint requests to: Michael R. Jaff, DO, Harvard Medical School, Vascular Center, Massachusetts General Hospital, Boston, MA

References 

  1. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study (The Cardiovascular Health Study Group). Arterioscler Thromb Vasc Biol. 1999;19:538–545
  2. McDermott MM, Mehta S, Ahn H, et al. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. 1997;12:209–215
  3. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324
  4. Hirsch AT, Murphy TP, Lovell MB, et al. Gaps in public knowledge of peripheral arterial disease: The first national PAD public awareness survey. Circulation. 2007;116:2086–2094
  5. Hooi JD, Kester AD, Stoffers HE, et al. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: A longitudinal study. Am J Epidemiol. 2001;153:666–672
  6. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc. 1985;33:13–18
  7. Dagenais GR, Maurice S, Robitaille NM, et al. Intermittent claudication in Quebec men from 1974-1986: The Quebec Cardiovascular Study. Clin Invest Med. 1991;14:93–100
  8. Hiatt WR, Goldstone J, Smith SC, et al. Atherosclerotic peripheral vascular disease symposium II: Nomenclature for vascular diseases. Circulation. 2008;118:2826–2829
  9. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005;366:1773–1783
  10. Hooi JD, Stoffers HE, Knottnerus JA, et al. The prognosis of non-critical limb ischaemia: A systematic review of population-based evidence. Br J Gen Pract. 1999;49:49–55
  11. Catalano M. Epidemiology of critical limb ischaemia: North Italian data. Eur J Med. 1993;2:11–14
  12. O'Hare AM, Bertenthal D, Sidawy AN, et al. Renal insufficiency and use of revascularization among a national cohort of men with advanced lower extremity peripheral arterial disease. Clin J Am Soc Nephrol. 2006;1:297–304
  13. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease. Int Angiol. 2007;26:81–157
  14. Bernstein EF, Fronek A. Current status of noninvasive tests in the diagnosis of peripheral arterial disease. Surg Clin North Am. 1982;62:473–487
  15. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25:17–24
  16. Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: The Strong Heart Study. Circulation. 2004;109:733–739
  17. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: A meta-analysis. JAMA. 2008;300:197–208
  18. American Diabetes Association: Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26:3333–3341
  19. Rutherford RB, Lowenstein DH, Klein MF. Combining segmental systolic pressures and plethysmography to diagnose arterial occlusive disease of the legs. Am J Surg. 1979;138:211–218
  20. Darling RC, Raines JK, Brener BJ, et al. Quantitative segmental pulse volume recorder: A clinical tool. Surgery. 1972;72:873–877
  21. Mallouhi A, Rieger M, Czermak B, et al. Volume-rendered multidetector CT angiography: Noninvasive follow-up of patients treated with renal artery stents. Am J Roentgenol. 2003;180:233–239
  22. Willmann JK, Baumert B, Schertler T, et al. Aortoiliac and lower extremity arteries assessed with 16-detector row CT angiography: Prospective comparison with digital subtraction angiography. Radiology. 2005;236:1083–1093
  23. Wardlaw JM, Chappell FM, Best JJ, et al. Non-invasive imaging compared with intra-arterial angiography in the diagnosis of symptomatic carotid stenosis: A meta-analysis. Lancet. 2006;367:1503–1512
  24. Collins R, Burch J, Cranny G, et al. Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: Systematic review. BMJ. 2007;334:1257
  25. Leiner T, Tordoir JH, Kessels AG, et al. Comparison of treatment plans for peripheral arterial disease made with multi-station contrast medium-enhanced magnetic resonance angiography and duplex ultrasound scanning. J Vasc Surg. 2003;37:1255–1262
  26. US Food and Drug Administration. CfDEaR, public health advisory: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, Optimark, Magnevist, prohance, and MultiHance. http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htmAccessed September 8, 2006
  27. Kock MC, Adriaensen ME, Pattynama PM, et al. DSA versus multi-detector row CT angiography in peripheral arterial disease: Randomized controlled trial. Radiology. 2005;237:727–737
  28. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: A statement for healthcare professionals from the American Heart Association (American Heart Association Task Force on Risk Reduction). Circulation. 1997;96:3243–3247
  29. Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J. 1999;20:344–353
  30. Willigendael EM, Teijink JA, Bartelink ML, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004;40:1158–1165
  31. Aboyans V, Criqui MH, Denenberg JO, et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006;113:2623–2629
  32. Juergens JL, Barker NW, Hines EA. Arteriosclerosis obliterans: Review of 520 cases with special reference to pathogenic and prognostic factors. Circulation. 1960;21:188–195
  33. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication (Effects on the risk of peripheral vascular complications, myocardial infarction and mortality). Acta Med Scand. 1987;221:253–260
  34. Palumbo PJ, O'Fallon WM, Osmundson PJ, et al. Progression of peripheral occlusive arterial disease in diabetes mellitus (What factors are predictive?). Arch Intern Med. 1991;151:717–721
  35. Sise MJ, Shackford SR, Rowley WR, et al. Claudication in young adults: A frequently delayed diagnosis. J Vasc Surg. 1989;10:68–74
  36. Valentine RJ, Jackson MR, Modrall JG, et al. The progressive nature of peripheral arterial disease in young adults: A prospective analysis of white men referred to a vascular surgery service. J Vasc Surg. 1999;30:436–444
  37. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: A meta-analysis. Arch Intern Med. 1999;159:337–345
  38. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust. 1983;1:217–219
  39. Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ USA. 2003;3:277–281
  40. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service Report (The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives). JAMA. 2000;283:3244–3254
  41. Bansal MA, Cummings KM, Hyland A, et al. Stop-smoking medications: Who uses them, who misuses them, and who is misinformed about them?. Nicotine Tob Res. 2004;6(suppl 3):303–310
  42. Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1995-99. Morb Mortal Wkly Rep. 2002;51:300–303
  43. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195–1202
  44. Lancaster T, Stead L, Silagy C, et al. Effectiveness of interventions to help people stop smoking: Findings from the Cochrane Library. BMJ. 2000;321:355–358
  45. Roddy E. Bupropion and other non-nicotine pharmacotherapies. BMJ. 2004;328:509–511
  46. Safar ME, Frohlich ED. The arterial system in hypertension (A prospective view). Hypertension. 1995;26:10–14
  47. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation. 2003;107:2864–2869
  48. Kannel WB, Skinner JJ, Schwartz MJ, et al. Intermittent claudication (Incidence in the Framingham Study). Circulation. 1970;41:875–883
  49. Safar ME, Priollet P, Luizy F, et al. Peripheral arterial disease and isolated systolic hypertension: The ATTEST Study. J Hum Hypertens. 2009;23:182–187
  50. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: Diagnosis, evaluation, and treatment (A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research). Circulation. 2008;117:e510–e526
  51. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289:2560–2572
  52. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–2428
  53. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting—enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592
  54. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  55. Smith SC, Allen J, Blair SN, et al. Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363–2372
  56. Feringa HH, Karagiannis SE, van Waning VH, et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg. 2007;45:936–943
  57. McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003;107:757–761
  58. Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114:359–364
  59. Hirsch AT, Haskal ZJ, Hertzer NR, et al. Practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the Arab Cooperation Council/AHA, Task Force on Practice Guidelines, 2005 (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–e654
  60. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678–686
  61. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27:267–274discussion 274-265
  62. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996;23:104–115
  63. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication (Online). Cochrane Database Syst Rev. 2000;CD000990
  64. McDermott MM, Ades P, Guralnik JM, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: A randomized controlled trial. JAMA. 2009;301:165–174
  65. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain (A meta-analysis). JAMA. 1995;274:975–980
  66. Zwierska I, Walker RD, Choksy SA, et al. Relative tolerance to upper- and lower-limb aerobic exercise in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg. 2006;31:157–163
  67. Walters TK, Mitchell DC, Wood RF. Low-dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease. Br J Surg. 1993;80:1266–1268
  68. Cassar K, Bachoo P, Ford I, et al. Platelet activation is increased in peripheral arterial disease. J Vasc Surg. 2003;38:99–103
  69. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106
  70. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine (Results from STIMS, the Swedish Ticlopidine Multicentre Study). J Intern Med. 1990;227:301–308
  71. Cacoub PP, Bhatt DL, Steg PG, et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30:192–201
  72. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982–1988
  73. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339
  74. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53:298–304
  75. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–431
  76. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  77. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139
  78. Goto S. Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atherosclerosis Suppl. 2005;6:3–11
  79. Regensteiner JG, Ware JE, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: Meta-analysis of six randomized controlled trials. J Am Geriatr Soc. 2002;50:1939–1946
  80. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523–530
  81. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041–2050
  82. Nony P, Boissel JP, Lievre M, et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients (A meta-analysis). Eur J Clin Pharmacol. 1994;46:191–196
  83. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Derm. 1994;30:603–621
  84. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized controlled trials. CMAJ. 1996;155:1053–1059
  85. Barradell LB, Brogden RN. Oral naftidrofuryl (A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease). Drugs Aging. 1996;8:299–322
  86. De Backer T, Vander Stichele R, Lehert P, et al. Naftidrofuryl for intermittent claudication: Meta-analysis based on individual patient data. BMJ. 2009;338:b603
  87. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet. 2002;359:2053–2058
  88. Rajagopalan S, Mohler ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933–1938
  89. Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial. Hum Gene Ther. 2006;17:683–691
  90. Creager MA, Olin JW, Belch J, et al: A randomized, double-blind, placebo-controlled, parallel group study of ad2/hypoxia inducible factor (HIF-1a/vp16) in patients with intermittent claudication. Paper presented at: The American College of Cardiology Annual Scientific Sessions; March 2009; Orlando, FL
  91. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet. 2002;360:427–435
  92. Linares-Palomino JP, Gutierrez J, Lopez-Espada C, et al. Genomic, serologic, and clinical case-control study of Chlamydia pneumoniae and peripheral artery occlusive disease. J Vasc Surg. 2004;40:359–366
  93. Jaff MR, Dale RA, Creager MA, et al. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: Prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1). Circulation. 2009;119:452–458

PII: S1089-2516(09)00065-1

doi: 10.1053/j.tvir.2009.10.002

Techniques in Vascular & Interventional Radiology
Volume 13, Issue 1 , Pages 2-10 , March 2010

Article Tools